Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Equity-to-Asset is 0.09 as of Dec. 2025, which is 10% below its 10-year median of 0.10. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Labiana Health ranks worse than 90.67% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Labiana Health's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €5.08 Mil. Labiana Health's Total Assets for the quarter that ended in Dec. 2025 was €57.54 Mil.
Therefore, Labiana Health's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.09.
The historical rank and industry rank for Labiana Health's Equity-to-Asset or its related term are showing as below:
XMAD:LAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06 Med: 0.1 Max: 0.22
Current: 0.09
During the past 6 years, the highest Equity to Asset Ratio of Labiana Health was 0.22. The lowest was 0.06. And the median was 0.10.
XMAD:LAB's Equity-to-Asset is ranked worse than 90.67% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XMAD:LAB: 0.09
Labiana Health (XMAD:LAB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Labiana Health Equity-to-Asset Related Terms
Labiana Health Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Labiana Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Labiana Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Labiana Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Equity-to-Asset of 0.09 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Labiana Health and its competitors. This is 10% below median its historical median of 0.10. Over the past decade, Labiana Health's Equity-to-Asset has ranged from 0.06 to 0.22. According to the industry distribution chart, Labiana Health ranks #914 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Labiana Health's Equity-to-Asset too high?
Labiana Health's current Equity-to-Asset of 0.09 is 10% below median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.22. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Labiana Health's value of 0.09 is 85.2% below this industry median. Based on the distribution chart, Labiana Health ranks #914 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #914 out of 1008 companies for Equity-to-Asset. This places Labiana Health in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Labiana Health's value of 0.09 is 85.2% below this benchmark. Historically, Labiana Health's own Equity-to-Asset has ranged from 0.06 to 0.22 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 0.61, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Equity-to-Asset of 0.09 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Equity-to-Asset is 0.09, which is 10% below median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Equity-to-Asset is 0.09, which is 10% below median its 10-year median of 0.10 and 85.2% below the Drug Manufacturers industry median of 0.61. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Equity-to-Asset is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Equity-to-Asset: 0.09 (10% below median its 10-year median of 0.10)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#914 of 1008)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
